Cancer Research UK logo.
SearchDonate
  • Search

A study looking at EZN 4176 for advanced prostate cancer

Overview

Cancer types:

Prostate cancer

Status:

Results

Phase:

Phase 1

Details

This study looked at a drug called EZN 4176 for prostate cancer that has spread to another part of the body and is no longer responding to hormone therapy.

Doctors often use hormone therapy to treat prostate cancer. This can keep it under control for long periods of time. But researchers are looking for treatments that will help men who have prostate cancer that stops responding to hormone therapy.

Prostate cancer needs the hormone testosterone to grow. The cancer cells have receptors that the testosterone can lock into. This encourages the cancer cells to grow.

In this study, the researchers looked at a drug called EZN 4176. It stops cancer cells from making more receptors and so doctors hoped it would help to slow cancer growth.

The aims of this study were to

  • Find the highest safe dose of EZN 4176

  • See if it slows the growth of prostate cancer that is no longer responding to hormone therapy

  • Learn more about the side effects

Recruitment start: 1 April 2011

Recruitment end: 30 November 2012

How to join

Please note: In order to you will need to discuss it with your doctor, unless otherwise specified.

Chief investigators

Prof Johann de Bono

Supported by

Enzon Pharmaceuticals Inc

Last reviewed: 17 May 2015

CRUK internal database number: 9344

Help and support